A leading coronavirus vaccine developer has been forced to hold a late-stage trial after a UK volunteer candidate suffered a suspected serious adverse reaction.
AstraZeneca Plc - which is working alongside the University of Oxford - has confirmed it had had to pause development of the vaccine "to allow review of safety data".
It is unclear whether the vaccine front runner made the decision itself or was ordered by a regulatory agency, reports Stat News.
The nature of the adverse reaction or when it occurred are not known but the participant is reportedly expected to recover. The AstraZeneca spokesperson went on to describe the pause as a "routine action" which must happen whenever a "potentially unexplained illness" occurs in one of its